Appropriate use of antimicrobials for drug-resistant pneumonia: Focus on the significance of β-lactam-resistant Streptococcus pneumoniae

Clinical Infectious Diseases

Volumn 34, Issue SUPPL. 1, 2002, Pages

  File Jr , Thomas M ^a  

^a SUMMA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEFOTAXIME; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; IMIPENEM; MACROLIDE; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL VIRULENCE; BACTERIUM ISOLATION; DISEASE SEVERITY; HOSPITALIZATION; HUMAN; MICROANGIOPATHY; MORTALITY; PHARMACODYNAMICS; PRESCRIPTION; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE;

BETA-LACTAM RESISTANCE; BETA-LACTAMS; HUMANS; PNEUMONIA, PNEUMOCOCCAL; PRACTICE GUIDELINES; STREPTOCOCCUS PNEUMONIAE;

EID: 0036499039     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/324526     Document Type: Article

References (52)

1. Prognosis and outcomes of patients with community-acquired pneumonia: A meta-analysis
2. Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae
3. Practice guidelines for the management of community-acquired pneumonia in adults
4. Canadian guidelines for the initial management of community-acquired pneumonia: An evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society
5. A resistant pneumococcus
6. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolated in the United States, 1997-1998
7. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995
8. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 US surveillance study
9. Susceptibility of Streptococcus pneumonia, Haemophilus influenzae, and Moraxella catarhallis to oral agents: Results of a 1998 U.S. outpatient surveillance study
10. Antibiotic resistance in Streptococcus pneumoniae
11. A review of antibiotic resistance patterns of Streptococcus pneumoniae in Europe
12. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada
13. Managing antibiotic resistance
14. Drug-resistant Streptococcus pneumoniae
15. Impaired bacteriologic response to oral cephalosporins in acute otitis media caused by pneumococci with intermediate resistance to penicillin
16. Bacteriologic response to oral cephalosporins: Are established susceptibility breakpoints appropriate in the case of acute otitis media?
17. Failure of cefotaxime in the treatment of meningitis due to relatively resistant Streptococcus pneumoniae
18. Drug-resistant pneumococcal meningitis in an American adult
19. Failure of chloramphenicol therapy in penicillin-resistant pneumococcal meningitis
20. Comparison of the response to antimicrobial therapy of penicillin-resistant and penicillin-susceptible pneumococcal disease
21. Treatment failure with use of a third-generation cephalosporin for penicillin-resistant pneumococcal meningitis: Case report and review
22. Bactericidal activity against cephalosporin-resistant Streptococcus pneumoniae in cerebrospinal fluid of children with acute bacterial meningitis
23. Antibiotic-resistant pneumococcal disease in South African children
24. Resistance to penicillin and cephalosporin and mortality, from severe pneumococcal pneumonia in Barcelona, Spain
25. Clinical outcome of invasive infections by penicillin-resistant Streptococcus pneumoniae in Korean children
26. Risk factors and course of illness among children with invasive penicillin-resistant Streptococcus pneumoniae. The Streptococcus pneumoniae Working Group
27. Management of community-acquired pneumonia in the era of pneumococcal resistance: A report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group
28. Community-acquired pneumonia due to penicillin-resistant pneumococci
29. Risk factors and response to antibiotic therapy in adults with bacteremic pneumonia caused by penicillin-resistant pneumococci
30. Community-acquired pneumonia in an adult due to a multiply-resistant pneumococcus
31. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997
32. Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence
33. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia
34. Comparative in vivo activity of gemifloxacin in a rat model of respiratory tract infection
35. Streptococcus pneumoniae respiratory tract infections
36. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
37. Penicillin dosing for pneumococcal pneumonia
38. Therapy for children with invasive pneumococcal infections
39. A pharmacologic evaluation of penicillin in children with purulent meningitis
40. Choosing an antibiotic on the basis of pharmacodynamics
41. Surveillance of multiple drug resistance patterns among Streptococcus pneumoniae in the United States
42. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States
43. The influence of mini-BAL cultures on patient outcomes: Implications for the antibiotic management of ventilator-associated pneumonia
44. Management of patients with community-acquired pneumonia in a primary care hospital: A critical evaluation
45. A prediction rule to identify low-risk patients with community-acquired pneumonia
46. ERS Task Force Report. Guidelines for management of adult community-acquired lower respiratory tract infections
47. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia
48. A controlled trial of a critical pathway for treatment of community-acquired pneumonia
49. Economic assessment of the community-acquired pneumonia intervention trial employing levofloxacin
50. Economic impact of antimicrobial resistance
51. Overview of resistance in the 1990s